Get the Stockscreener App
4.60
0.22%
-0.01
Oramed Pharmaceuticals Inc stock is traded at $4.60, with a volume of 360.79K.
It is down -0.22% in the last 24 hours and up +27.78% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
See More
Previous Close:
$4.61
Open:
$4.73
24h Volume:
360.79K
Relative Volume:
1.36
Market Cap:
$188.26M
Revenue:
$2.00M
Net Income/Loss:
$109.16M
P/E Ratio:
1.7805
EPS:
2.5835
Net Cash Flow:
$-9.11M
1W Performance:
-8.00%
1M Performance:
+27.78%
6M Performance:
+58.08%
1Y Performance:
+112.96%
1-Day Range:
$4.485
$4.825
1-Week Range:
$4.255
$5.11
52-Week Range:
$1.975
$5.19
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.60 | 196.85M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com - Investing.com South Africa
137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144 - Stock Titan
Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026 - Stock Titan
Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions - TipRanks
Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Value Benchmark - marketscreener.com
BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 3000E Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Value-Defensive Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Value Benchmark - marketscreener.com
Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1) - TradingView
Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1) - TradingView
These healthcare stocks are combining strong gains with reasonable prices - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - Finviz
Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP) - TradingView
Oramed's Pivot Pays Off: From Pharma Hopeful to Investment Powerhouse - BriefGlance
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORMP SEC FilingsOramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Daily Brief United States: Tesla , Adobe Systems, Nine Energy Service , Oramed Pharmaceuticals , Olin Corp, Earth Science Tech, Kardigan, Generac Holdings, General Motors, Nucor Corp and more - Smartkarma
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026 - GuruFocus
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oramed Pharmaceuticals Inc - TradingKey
Oramed Pharmaceuticals to join Russell 2000, 3000 indexes - Investing.com
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PR Newswire
Oramed (NNDM holder) lifts Nano Dimension stake to 7.2% and opposes proposed deal - Stock Titan
June 2026 Penny Stocks To Watch For Potential Growth - Yahoo Finance
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Oramed Pharmaceuticals (ORMP) Faces Selling Pressure; Key Levels in FocusTriple Bottom - newsline.com
Oramed Pharmaceuticals Q4 2025 Earnings: Positive EPS Surprise Driven by Non-Operating IncomeEarnings Beat Alert - newsline.com
Oramed Pharmaceuticals Inc. (ORMP) Q4 2025 Earnings: Surprise Profitability on Milestone RevenueEarnings Expansion Phase - newsline.com
ORMP Should I Buy - Intellectia AI
Oramed Pharmaceuticals (ORMP) Holds Near Key Support Amid Modest DeclineDemand Zone - The Legal Advocate
ORMPOramed Pharmaceuticals Inc Stock Price and Quote - Finviz
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy - openPR.com
Oramed Pharmaceuticals (ORMP) Drops 8.9%: Support Level Under PressureNAAIM Exposure - The Legal Advocate
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Q4 2025 Results Meet Expectations — Revenue $N/AMargin Compression Risk - newsline.com
Oramed Pharmaceuticals Inc. Q1 2026 Financial Report: Key Investments, Marketable Securities, and Forward-Looking Statements - Minichart
Oramed: Q1 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary - TradingView
Oramed (NASDAQ: ORMP) swings to $38.3M Q1 profit on Alpha Tau and Scilex gains - Stock Titan
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oramed Pharmaceuticals Inc Stock (ORMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO |
Jul 01 '26 |
Sale |
4.46 |
137,000 |
611,431 |
1,023,384 |
| Gabay Avraham | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.51 |
73,360 |
330,744 |
671,785 |
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):